Table 1.
Characteristics of included randomised controlled trials.
| Study | Intervention | Cancer type | Sex, Male | Sample Size | Age years Mean (Standard Deviation) |
Median follow-up | Events reported |
|---|---|---|---|---|---|---|---|
| NCT02576509 | Nivolumab | Hepatocellular Carcinoma | 84.9% | 367 | 63.9 (10.61) | 3.5y | ClinicalTrials.gov |
| Sorafenib | 363 | 64.5 (10.91) | |||||
| NCT02231749 | Nivolumab + Ipilimumab | Renal Cell Carcinoma | 73.7% | 547 | 61.1 (9.76) | 31m | ClinicalTrials.gov |
| Sunitinib | 535 | 60.7 (10.10) | |||||
| NCT02481830 | Nivolumab | Small-cell Lung Cancer | 61.7% | 282 | 61.5 (9.2) | NR | ClinicalTrials.gov |
| Chemotherapy | 265 | 61.6 (8.4) | |||||
| NCT02041533 | Nivolumab | NSCLC | 61.4% | 267 | 62.8 (10.25) | 18m | ClinicalTrials.gov |
| Carbone 2017 | Chemotherapy | 263 | 63.4 (9.63) | Carbone 2017 | |||
| NCT03215706 | Nivolumab + Ipilimumab + Chemotherapy | NSCLC | 70.1% | 358 | 65.0 (8.3) | 23m | ClinicalTrials.gov |
| Chemotherapy | 349 | 65.0 (10.3) | |||||
| NCT03950674 | Nivolumab + Chemotherapy | NSCLC | 77.5% | 25 | 59.6 (12.7) | NR | ClinicalTrials.gov |
| Chemotherapy | 15 | 60.9 (11.8) | |||||
| NCT02579863 | Pembrolizumab + Lenalidomide + Dexamethasone | Multiple Myeloma | 46.5% | 154 | 74.4 (6.0) | 30m | Usmani 2019 |
| Usmani 2019 | Lenalidomide + Dexamethasone | 148 | 74.3 (5.9) | ||||
| NCT02576977 | Pembrolizumab+Pomalidomide+Dexamethasone | Multiple Myeloma | 62.5% | 122 | 65.5 (9.3) | 33m | Mateos 2019 |
| Pomalidomide+Dexamethasone | 123 | 66.4 (10.0) | |||||
| NCT02494583 | Pembrolizumab + Chemotherapy | Gastric or Gastroesophageal Junction | 72.6% | 250 | 60.9 (11.6) | 42m | ClinicalTrials.gov |
| Pembrolizumab | 254 | 59.9 (11.6) | |||||
| Chemotherapy | 244 | 60.7 (12.7) | |||||
| NCT02252042 | Pembrolizumab | Head and Neck | 83.2% | 246 | 60.3 (9.8) | 27m | Cohen 2019 |
| Standard Treatment | 234 | 60.2 (8.6) | |||||
| NCT01704287 | Pembrolizumab 2 mg/kg | Melanoma | 60.6% | 178 | 59.5 (14.9) | 75 m | ClinicalTrials.gov |
| Pembrolizumab 10 mg/kg | 179 | 60.1 (13.3) | |||||
| Chemotherapy | 171 | 60.5 (12.7) | |||||
| NCT02302807 | Atezolizumab 1200mg every 21d | Urothelial Bladder | 77.1% | 459 | 65.9 (9.6) | 46m | Powles 2018 |
| Chemotherapy | 443 | 66.1 (9.3) | |||||
| NCT02420821 | Atezolizumab + Bevacizumab | Renal Cell Carcinoma | 73.1% | ClinicalTrials.gov | |||
| Sunitinib | |||||||
| NCT02908672 | Atezolizumab + Cobimetinib + Vemurafenib | Melanoma | 58.2% | 230 | 54.0 (14.2) | 9m | ClinicalTrials.gov |
| Cobimetinib + Vemurafenib | 281 | 53.2 (14.1) | |||||
| NCT00094653 | Ipilimumab Plus gp100 | Melanoma | 59.3% | 380 | 55.6 | 61.6m | ClinicalTrials.gov |
| Ipilimumab | 131 | 56.8 | |||||
| gp100 | 132 | 57.4 | |||||
| NCT02516241 | Durvalumab±tremelimumab | Urothelial carcinoma | 75.5% | 340 | 67 | 41.2m | Powles 2020 |
| Powles 2020 | Durvalumab | 348 | 67 | ||||
| Chemotherapy | 313 | 68 | |||||
| NCT03043872 | Durvalumab±tremelimumab +Chemotherapy | SCLC | 71.6% | 266 | 63 | 25.1m | Goldman 2021 |
| Durvalumab +Chemotherapy | 265 | 62 | |||||
| Chemotherapy | 266 | 63 | |||||
| NCT02569242 | Nivolumab | Oesophageal squamous cell carcinoma | 89% | 209 | 64 | Kato 2019 | |
| Kato 2019 | Chemotherapy | 208 | 67 | ||||
| NCT02523313 | Ipilimumab+Nivolumab | Melanoma | 57% | 55 | 52 | 28.4m | Zimmer 2020 |
| Zimmer 2020 | Nivolumab | 56 | 57 | ||||
| Placebo | 51 | 58.5 | |||||
| NCT00527735 | Ipilimumab + Paclitaxel/Carboplatin | NSCLC/SCLC | 74.6% | 222 | / | NR | ClinicalTrials.gov |
| Paclitaxel/Carboplatin | 109 | / |